ReviewGlobal medical genetics2023
VEXAS Syndrome-Review.
Review in Global medical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Clinical characteristics and a screening tool for VEXAS syndrome: a case-control study from China.Orphanet journal of rare diseases · 2026Article
- A fatal case of VEXAS syndrome with a brief review.Journal of vascular surgery cases and innovative techniques · 2026Article
- VEXAS Syndrome and Substance Use Disorders: A Large-Scale, Propensity-Matched, Case-Control Analysis Revealing Immune-Mediated Comorbidities.International journal of dermatology · 2026Article
- Article
- A Vexing Diagnosis: ENT Presentation of Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome.Cureus · 2025Article
- Article
- VEXAS syndrome-associated tumefactive demyelination.Journal of neurology · 2025Article
- Multiple Erythematous Oedematous Plaques on the Neck of a 68-year-old Man: A Quiz.Acta dermato-venereologica · 2025Article
- VEXAS Syndrome: An Overlooked Threat.Balkan medical journal · 2025Article
- VEXAS syndrome with p.Met41LeuJAAD case reports · 2025Article
- VEXAS, Chediak-Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?Cellular & molecular biology letters · 2025Review
- UtilizingJournal of developmental biology · 2025Review
- Promise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature.Open access rheumatology : research and reviews · 2025Article
- VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.Journal of clinical medicine · 2024Review
- Rare primary vasculitis: update on multiple complex diseases and the new kids on the block.Advances in rheumatology (London, England) · 2024Review
- Inflammatory turmoil within: an exploration of autoinflammatory disease genetic underpinnings, clinical presentations, and therapeutic approaches.Advances in rheumatology (London, England) · 2024Review
- The Emerging Spectrum of Somatic Mutation in Rheumatic Disease: Clonal Hematopoiesis Connects Aging With Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined refractory adult-onset autoinflammatory syndrome caused by somatic mutations in the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene in hematopoietic stem and progenitor cells, resulting in a shift in UBA1 isoform expression. Thus, patients develop a spectrum of systemic inflammatory manifestations and hematologic symptoms. To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality rate, VEXAS syndrome needs to be taken seriously by physicians in all specialties. This article aims to describe the key features, pathogenesis, and clinical manifestations of VEXAS syndrome to better understand the targeted treatment and improve the prognosis of VEXAS syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.